Original research
by
Meyerson, Beth E. et al
Release Date
2022
Geography
USA
Language of Resource
English
Full Text Available
Yes
Open Access / OK to Reproduce
Yes
Peer Reviewed
Yes
Objective
To understand patient experience of federal regulatory changes governing methadone and buprenorphine (MOUD) access in Arizona during the COVID-19 pandemic.
Findings/Key points
MOUD patients in Arizona were not offered many of the federally allowed flexibilities for access that were designed to reduce their need to be at the clinic. All participants expressed that daily clinic visits interrupted their work and home lives and desired more take-home dosing and home delivery options.
Design/methods
Interviews (n=131)
Keywords
Policy/Regulatory
About PWUD
Substitution/OAT
Carries/take-home doses
